Piperidine, 4-(1,4-dioxan-2-ylmethoxy)-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: Piperidine, 4-(1,4-dioxan-2-ylmethoxy)-
• 英文别名: 4-(1,4-dioxan-2-ylmethoxy)piperidine
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.26
• InChiKey: FCLPKNMBDOADLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE MCL-1 ET MÉTHODES D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019035911A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本公开提供了式(I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗疾病和病况，包括癌症方面是有用的。还提供了包含式(I)化合物的药物组合物。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US10676485B2

  公开（公告）日：2020-06-09

  The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本公开提供了式 (I) 的化合物 其中 A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X 和 Y 具有说明书中定义的任一值，及其药学上可接受的盐，可用作治疗疾病和病症（包括癌症）的药物。还提供了包含式（I）化合物的药物组合物。
• MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：EP3652184A1

  公开（公告）日：2020-05-20
• Macrocyclic MCL-1 Inhibitors and Methods of Use
  申请人：AbbVie Inc.

  公开号：US20200325153A1

  公开（公告）日：2020-10-15

  The present disclosure provides for compounds of formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).